基于网络药理学与实验验证探究金丝桃苷干预糖尿病肾病的作用机制OA
Exploring the Mechanism of Hyperoside Intervention in Diabetic Nephropathy Based on Network Pharmacology and Experimental Validation
目的:通过网络药理学及动物实验研究探讨金丝桃苷(Hyp)干预糖尿病肾病(DKD)的潜在作用机制.方法:利用TCMSP和Uniprot数据库预测Hyp相关靶点基因,GAD数据库得到DKD相关靶点基因名,通过Hyp靶点和DKD靶点相互作用关系PPI网络构建交集网络,Degree值筛选核心靶点,并使用 DAVID 数据库对Hyp的DKD保护作用靶点进行 GO 分析,预测Hyp干预糖尿病肾病的作用机制.8周龄C578L/6J雄性小鼠32只,随机选取8只为空白对照组(N组),使用普通饲料喂养,其余采用高脂联合链脲佐菌素(STZ)的方法建立DKD小鼠模型.造模成功小鼠随机分为模型组(M组)、金丝桃苷组[H组,200 mg/(kg·d)]和辛代他汀组[S组,5.2 mg/(kg·d)],每组8只,灌胃给药16周,每天1次.使用免疫组化和免疫印迹技术检测ERK1/2信号通路相关蛋白及下游炎症因子,从分子水平探讨Hyp对DKD的干预作用机制.结果:网络药理学分析得到核心靶点蛋白5个,对应的基因名称分别为TP53、ICAM-1、HSP90AA1、ESR1、EGFR,生物过程及信号转导通路20条(P<0.05),预测ERK1/2信号通路可能是Hyp干预DKD的主要通路之一.动物实验结果表明,与模型组相比,Hyp干预后金丝桃苷组小鼠肾脏组织中Ras/Raf/MEK/ERK1/2通路有关蛋白Ras、Raf、MEK、ERK1/2、p-ERK1/2蛋白表达减少,其下游炎症因子NF-κB、TNF-α、MCP-1和ICAM-1的表达也明显减少,差异具有统计学意义(P<0.01,P<0.05).结论:Hyp可通过抑制Ras/Raf/MEK/ERK1/2信号转导通路的活化,进一步抑制下游炎性因子产生,保护肾脏,改善肾功能,延缓DKD的发生和发展.
Objective:To investigate the potential mechanism of Hyperoside(Hyp)in the intervention of diabetic nephropathy(DKD)through network pharmacology and animal experiments.Methods:Target genes related to Hyp were predicted using the TCMSP and Uniprot databases.DKD-related target genes were obtained from the GAD database.The intersection network was constructed using PPI networks of Hyp and DKD targets,and core targets were screened based on Degree values.GO analysis of the targets for Hyp's protective effect on DKD was conducted using the DAVID database to predict the mechanism of Hyp in the intervention of diabetic nephropathy.Thirty-two male C57BL/6J mice at 8 weeks of age were randomly divided into a blank control group(N group,8 mice)fed with regular diet,and the remaining mice were used to establish DKD models using a high-fat diet combined with streptozotocin(STZ).Successfully modeled mice were randomly divided into a model group(M group),a Hyperoside group(H group,200 mg/(kg·d)),and a Rosuvastatin group(S group,5.2 mg/(kg·d)),with 8 mice in each group.Treatment was administered by gavage for 16 weeks,once daily.Immunohistochemistry and Western blotting were used to detect ERK1/2 signaling pathway-related proteins and downstream inflammatory factors to explore the mechanism of Hyp's intervention in DKD at the molecular level.Results:Network pharmacology analysis identified five core target proteins:TP53,ICAM-1,HSP90AA1,ESR1,and EGFR,and 20 biological processes and signaling pathways(P<0.05).The ERK1/2 signaling pathway was predicted to be one of the main pathways through which Hyp intervenes in DKD.Animal experiment results showed that compared with the model group,the expression of Ras,Raf,MEK,ERK1/2,and p-ERK1/2 proteins related to the Ras/Raf/MEK/ERK1/2 pathway was reduced in the kidneys of mice in the Hyperoside group.Additionally,the expression of downstream inflammatory factors NF-κB,TNF-α,MCP-1,and ICAM-1 was also significantly decreased,with statistically significant differences(P<0.01,P<0.05).Conclusion:Hyp can protect the kidneys and improve renal function by inhibiting the activation of the Ras/Raf/MEK/ERK1/2 signaling pathway and further suppressing the production of downstream inflammatory factors,thereby delaying the onset and progression of DKD.
孙翠鸽;袁宇;闵冬雨;鞠业涛;王逸旋;胡丽萍
辽宁中医药大学,辽宁 沈阳 110847辽宁省检验检测认证中心辽宁省药品检验检测院,辽宁 沈阳 110036辽宁中医药大学附属医院,辽宁 沈阳 110032辽宁中医药大学附属医院,辽宁 沈阳 110032辽宁中医药大学,辽宁 沈阳 110847辽宁中医药大学,辽宁 沈阳 110847
金丝桃苷糖尿病肾病链脲佐菌素
HyperosideDiabetic nephropathyStreptozotocin
《中医药信息》 2025 (2)
34-41,8
辽宁省自然科学基金面上项目(2015010708)
评论